Detalhe da pesquisa
1.
The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy.
Breast Cancer Res
; 25(1): 32, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36978142
2.
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Cancer
; 126(22): 4847-4858, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32780421
3.
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.
Int J Cancer
; 145(3): 857-868, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30694523
4.
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
Int J Cancer
; 145(8): 2114-2121, 2019 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30901076
5.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 175(1): 265-266, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30632020
6.
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.
Breast Cancer Res Treat
; 174(2): 453-461, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30603996
7.
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
Anticancer Drugs
; 30(4): 394-401, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30875348
8.
Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 19(9): 1247-1258, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30100379
9.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 165(3): 573-583, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28664507
10.
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Eur J Cancer
; 198: 113480, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38154393
11.
Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors-Results of Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey.
Cancers (Basel)
; 15(22)2023 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38001688
12.
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT.
Geburtshilfe Frauenheilkd
; 82(10): 1055-1067, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36186151
13.
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.
Breast Care (Basel)
; 16(1): 50-58, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33716632
14.
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
J Clin Oncol
; 37(10): 799-808, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30785826
15.
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
Clin Cancer Res
; 22(23): 5747-5754, 2016 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27189162
16.
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Eur J Cancer
; 49(10): 2284-93, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23541564
17.
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.
PLoS One
; 8(12): e79775, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24312450
18.
Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine.
Breast Care (Basel)
; 7(1): 7-12, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22553466